Blog

Two exciting new CUP trials awaiting ethical approval before a Summer start

CUPEM The immunotherapy trial, to which we have contributed £100,000 on behalf of our donors, is now awaiting only ethical approval. Merck are providing/funding the drugs. The trial’s initiator and lead, Dr Harpreet Wasan of Hammersmith Hospital and Imperial College London, writes: ‘We hope to recruit 77 patients in total to test the benefit of immunotherapy in CUP and hopeRead more

Optimal care pathway for Australians with CUP

The Australian authorities have been working on an equivalent to our NICE Guideline for CUP and their ‘Optimal care pathway for people with cancer of unknown primary‘ is now out in draft for public consultation in Australia. Two members of our Medical Advisory Board were members of the expert group developing the care pathway: Dr Richard Osborne and Prof PennyRead more